AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) Director Ecor1 Capital, Llc acquired 152,367 shares of the firm’s stock in a transaction on Tuesday, November 17th. The stock was purchased at an average price of $45.66 per share, for a total transaction of $6,957,077.22. Following the transaction, the director directly owned 8,116,581 shares of the company’s stock, valued at approximately $370,603,088.46. This trade represents a 1.91% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Ecor1 Capital, Llc also recently made the following trade(s):
- On Wednesday, November 18th, Ecor1 Capital, Llc acquired 138,093 shares of AnaptysBio stock. The shares were purchased at an average cost of $46.54 per share, with a total value of $6,426,848.22.
- On Monday, November 16th, Ecor1 Capital, Llc bought 84,120 shares of AnaptysBio stock. The shares were purchased at an average price of $45.66 per share, with a total value of $3,840,919.20.
AnaptysBio Trading Up 3.2%
Shares of NASDAQ ANAB traded up $1.45 during trading hours on Wednesday, hitting $47.06. The company’s stock had a trading volume of 566,852 shares, compared to its average volume of 658,208. The company has a debt-to-equity ratio of 0.17, a quick ratio of 8.40 and a current ratio of 8.40. The stock has a market cap of $1.40 billion, a price-to-earnings ratio of 9.49 and a beta of 0.70. AnaptysBio, Inc. has a 12 month low of $22.07 and a 12 month high of $72.36. The business has a 50-day simple moving average of $49.35 and a 200-day simple moving average of $56.27.
AnaptysBio (NASDAQ:ANAB – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.84) by $1.95. The company had revenue of $30.27 million for the quarter, compared to the consensus estimate of $25.56 million. AnaptysBio had a negative return on equity of 17.54% and a net margin of 96.30%. On average, analysts anticipate that AnaptysBio, Inc. will post -1.30 earnings per share for the current fiscal year.
Analyst Ratings Changes
ANAB has been the topic of several research analyst reports. Wall Street Zen cut AnaptysBio from a “buy” rating to a “hold” rating in a research note on Sunday, October 4th. Leerink Partners dropped their price target on AnaptysBio from $90.00 to $81.00 and set an “outperform” rating for the company in a research note on Wednesday, September 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of AnaptysBio in a research note on Tuesday, September 22nd. Scotiabank cut shares of AnaptysBio to a “hold” rating and set a $70.00 price target on the stock. in a report on Tuesday, August 25th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of AnaptysBio from $70.00 to $60.00 and set an “overweight” rating on the stock in a research report on Wednesday, September 30th. Twelve research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, AnaptysBio currently has an average rating of “Moderate Buy” and an average target price of $75.67.
Read Our Latest Analysis on AnaptysBio
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in ANAB. BlackRock Inc. bought a new stake in shares of AnaptysBio in the 2nd quarter worth approximately $124,473,000. Affinity Asset Advisors LLC increased its position in AnaptysBio by 111.4% during the 1st quarter. Affinity Asset Advisors LLC now owns 940,000 shares of the biotechnology company’s stock valued at $52,132,000 after buying an additional 495,308 shares in the last quarter. Goldman Sachs Group Inc. increased its position in AnaptysBio by 45.6% during the 3rd quarter. Goldman Sachs Group Inc. now owns 850,343 shares of the biotechnology company’s stock valued at $42,738,000 after buying an additional 266,273 shares in the last quarter. Palo Alto Investors LP bought a new position in AnaptysBio during the 2nd quarter valued at approximately $40,735,508. Finally, First Light Asset Management LLC raised its stake in AnaptysBio by 2.9% during the second quarter. First Light Asset Management LLC now owns 582,004 shares of the biotechnology company’s stock valued at $39,285,000 after buying an additional 16,573 shares during the last quarter.
About AnaptysBio
AnaptysBio is a biotechnology company focused on developing antibody-based treatments for inflammatory and autoimmune diseases. Its research programs target immune pathways that may be involved in conditions with significant unmet medical needs. The company’s pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 pathway, and ANB032, an investigational antibody targeting BTLA. AnaptysBio has also developed imsidolimab, an antibody targeting the IL-36 receptor; global rights to that program were licensed to Vanda Pharmaceuticals.
Featured Articles
- Five stocks we like better than AnaptysBio
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.
